NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Inventory

Raw materials, work in progress, and finished goods held for sale.

NeoGenomics, Inc.NASDAQ: NEO

Inventory · Q2 FY2026 · quarter ended Jun 2026

Inventory falls 20.6% from a year ago

Inventory stood at $27.14M at the end of Q2 FY2026, down 20.6% from a year earlier and down 9.0% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.

Context

  • Inventory amounted to 2.0% of total assets at the end of Q2 FY2026, down 0.4 pp from a year earlier.
  • Inventory increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether inventory keeps falling in the next quarterly balance sheet after a -20.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.14M-9.0% QoQ
Last fiscal yearDec 2025
$28.57M+6.8% YoY
Year agoJun 2025
$34.17M-20.6% since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%——
1 year+6.8%——
3-year CAGR+5.6%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
28.57M USD
Year-over-year change
+6.8%
4-year CAGR
+5.1%

Inventory vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's Jun 2026 inventory of $27.14M is the 3rd highest of the 10 companies compared; the peer median is $17.76M.
  • Its year-over-year change of -20.6% is the lowest of 8, against a peer median of +3.3%.
  • Inventory amounts to 2.0% of total assets for NEO, versus a peer median of 1.9%.
NEO Competitors Peer median
Inventory for NEO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GHGuardant Health, Inc.Sep 2026$93.49M +3.3%+18.5%5.0%
MYGNMyriad Genetics, Inc.Mar 2026$27.9M -1.4%+15.0%4.1%
NEONeoGenomics, Inc.Jun 2026$27.14M -20.6%+5.6%2.0%
VCYTVeracyte, Inc.Jun 2026$22.66M -9.4%+12.9%1.5%
WGSGeneDx Holdings Corp.Jun 2026$17.82M +49.3%+0.7%3.7%
GRALGRAIL, Inc.Jun 2026$17.76M -10.0%-6.8%0.6%
CSTLCastle Biosciences, Inc.Mar 2026$10.46M +52.7%+37.1%1.9%
PSNLPersonalis, Inc.Mar 2026$6.93M +64.5%-1.3%2.1%
XGNExagen Inc.Mar 2026$0 ——0.0%
BDSXBiodesix, Inc.Mar 2026$0 ——0.0%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $17.76M+3.3%+12.9%1.9%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents316.83M263.18M342.49M367.01M159.62M
Short-term Investments198.56M174.81M72.72M19.83M0
Net Receivables112.13M119.71M131.26M150.54M159.24M
Inventory23.4M24.28M24.16M26.75M28.57M
Other Current Assets18.24M8.08M8.2M11.72M7.42M
Total Current Assets681.51M605.29M596.81M596.02M376.29M
Property, Plant & Equipment (Net)211.66M198.61M183.78M173.69M163.28M
Goodwill527.12M522.77M522.77M522.77M524.34M
Intangible Assets442.33M408.26M373.13M339.68M286.53M
Long-term Investments236K31K000
Tax Assets55.48M34.75M000
Other Non-current Assets(48.54M)(29.67M)4.74M5.89M9.39M
Total Non-current Assets1.19B1.13B1.08B1.04B983.54M
Total Assets1.87B1.74B1.68B1.64B1.36B
Account Payables17.92M20.51M20.33M21.61M23.09M
Short-term Debt1.14M00200.78M4.78M
Tax Payables00000
Deferred Revenue5.19M7.56M2.13M409K0
Other Current Liabilities16.66M15.07M53.16M62.44M60.43M
Total Current Liabilities87.23M89.93M96.3M301.24M88.3M
Long-term Debt532.48M535.32M538.2M340.34M404.68M
Deferred Tax Liabilities55.48M34.75M24.29M21.51M18.22M
Deferred Revenue (Non-current)917K19K00386K
Other Non-current Liabilities13.03M13.06M13.03M11.77M(51.14M)
Total Non-current Liabilities674.27M652.08M643.39M434.46M434.97M
Total Liabilities761.5M742.01M739.69M735.7M523.27M
Common Stock124K127K127K128K129K
Retained Earnings(14.84M)(159.09M)(247.06M)(325.78M)(433.81M)
Accumulated OCI(638K)(3.9M)(1.67M)(206K)4K
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.11B998.02M941.54M902.34M836.56M
Total Debt612.79M610.93M611.68M605.33M472.28M
Net Debt295.96M347.75M269.19M238.32M312.66M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.